Marconato L, Bonfanti U, Stefanello D, Lorenzo M R, Romanelli G, Comazzi S, Zini E
Clinica Veterinaria L'Arca, Naples, Italy.
Vet Comp Oncol. 2008 Jun;6(2):80-9. doi: 10.1111/j.1476-5829.2007.00141.x.
Cytosine arabinoside (ara-C) is a component of many protocols for the treatment of acute leukaemia and non-Hodgkin lymphomas in humans. The aim of the study was to prospectively evaluate the efficacy of ara-C in a myeloablative regimen in a cohort of canine lymphomas with bone marrow involvement. Seventeen dogs were enrolled. Eight were treated with a VCAA-based protocol (Group 1) and nine with the same regimen added with ara-C (Group 2). Ara-C was administered on a 5-day schedule as an i.v. continuous infusion at the dose of 150 mg m(-2) per day for five consecutive days. During treatment complete remission (CR) was achieved in two dogs in Group 1 and in eight dogs in Group 2. CR rate was significantly higher in Group 2 (P < 0.01). Median survival was 72.5 days (range 6-174) in Group 1 and 243 days (range 73-635) in Group 2. Survival was significantly longer in Group 2 (P < 0.001). Both protocols were well tolerated, with a low incidence of adverse events. Ara-C added to a VCAA-based protocol appears to be safe and beneficial in dogs with stage V lymphoma. Incorporation of the nucleoside analogue might be crucial for the development of future therapeutic strategies in dogs.
阿糖胞苷（ara-C）是人类急性白血病和非霍奇金淋巴瘤多种治疗方案的组成部分。本研究的目的是前瞻性评估阿糖胞苷在一组有骨髓受累的犬淋巴瘤清髓方案中的疗效。纳入了17只犬。8只犬接受基于VCAA的方案治疗（第1组），9只犬接受相同方案加用阿糖胞苷治疗（第2组）。阿糖胞苷按5天疗程静脉持续输注给药，剂量为每天150mg/m²，连续5天。治疗期间，第1组有2只犬达到完全缓解（CR），第2组有8只犬达到CR。第2组的CR率显著更高（P<0.01）。第1组的中位生存期为72.5天（范围6 - 174天），第2组为243天（范围73 - 635天）。第2组的生存期显著更长（P<0.001）。两种方案耐受性均良好，不良事件发生率低。在基于VCAA的方案中加用阿糖胞苷对V期淋巴瘤犬似乎是安全且有益的。核苷类似物的加入可能对犬未来治疗策略的发展至关重要。
